<DOC>
	<DOCNO>NCT00864240</DOCNO>
	<brief_summary>To determine dose-response relationship Clobex TM ( clobetasol propionate ) Lotion , 0.05 % . This information use estimate ED50 , D1 , D2 parameter use full bioequivalence study .</brief_summary>
	<brief_title>The Dose-response `` Pilot '' Study Topically Delivered Clobetasol Propionate Lotion Healthy Adult Subjects</brief_title>
	<detailed_description>Study Type : Interventional Study Design : Randomized , open label , one period , dose response , vasoconstrictor assay study . Official Title : Dose Response Clobex 0.05 % Lotion Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Â· Vasoconstrictor Response</detailed_description>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>Nontobaccousing female subject , 18 50 year age , inclusive . A demonstrated blanching response Clobex TM ( clobetasol propionate ) Lotion , 0.05 % . A body mass index ( BMI ) 30 kg/m2 le calculated accord Novum Standard Operating Procedures . Good health determine lack clinically significant abnormality medical history clinical assessment , judge Investigator . Signed date informed consent form meet criteria current FDA regulation . History allergy systemic topical corticosteroid ( include clobetasol ) cream , lotion , ointment , gel , cotton , soap , cosmetic , rubber , tape , opinion Investigator would compromise safety subject study . Presence skin condition coloration would interfere placement test site response assessment skin blanching . Significant history current evidence chronic infectious disease , system disorder ( especially hypertension circulatory disease ) , organ dysfunction . Presence medical condition require regular treatment prescription drug . Drug alcohol addiction require treatment ( inpatient outpatient ) 12 month prior dose . Use topical dermatological drug therapy ( include topical corticosteroid ) flexor surface ventral forearm 30 day prior dose . Use tobacco product 30 day prior dose . Receipt drug part research study within 30 day prior initial study dose . Pregnant lactating .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Vasoconstriction</keyword>
	<keyword>Clobetasol</keyword>
	<keyword>Healthy adult female</keyword>
</DOC>